PDC DDL 8272An IAVI scientist working on product development at the IAVI Vaccine Design and Development Lab. Photo credit: Joy Glenn

IAVI develops vaccine candidates and other biomedical innovations and manages clinical research with partners in academic, biotechnology, pharmaceutical, and government institutions. IAVI also provides translational research services and support to other organizations in the field, assisting them with the complex process of transitioning innovations from the laboratory into clinical trials. This includes providing assistance with manufacturing protocols and clinical and regulatory filings.

Product Development Center

In 2013, the Bill & Melinda Gates Foundation (BMGF) funded IAVI to create the Vaccine Product Development Center (VxPDC) to assist investigators affiliated with BMGF’s Collaboration for AIDS Vaccine Discovery with the complex process of transitioning vaccine candidates from the laboratory to the clinic. Subsequently, IAVI renamed it the Product Development Center (PDC), extending this translational expertise to other partners – whether academic, nonprofit, government, or industry – that are advancing new HIV prevention products. The PDC fills a critical gap in the development process for new vaccines and other biomedical innovations. Today, investigators from the U.S. National Institutes of Health and European funding partners are among those who utilize IAVI’s PDC.

pdc

The PDC provides:

  • A team of pharmaceutical development experts who collectively have advanced hundreds of projects through global regulatory agencies.
  • An extensive network of Contract Research Organizations, Contract Manufacturing Organizations, and technology partners to accelerate development and minimize risk.
  • Access to clinical research networks around the world, including in Africa and India.
  • Over 20 years of HIV vaccine development experience from projects using a wide range of technology platforms.

Recent accomplishments include:

  • Assisting an academic team with the development of a broadly neutralizing antibody discovered by IAVI. The antibody was scaled up and manufactured with PDC guidance and has entered Phase I clinical trials.
  • Advising investigators at IAVI’s Neutralizing Antibody Center on a program to develop an engineered vaccine candidate designed to trigger the production of antibodies. The PDC managed preclinical activities, and performed process and analytical development for the candidate, which is now in a Phase I clinical trial.
  • Providing manufacturing and regulatory expertise to university scientists in preparation for a Phase II efficacy study in 2019 of two broadly neutralizing antibodies.